Professor Onn Min Kon

Sub-specialties: Respiratory Infections, Tuberculosis, Non-tuberculous Mycobacteria, Sarcoidosis Interventional Bronchoscopy, General Respiratory Medicine, Respiratory Medicine, Asthma, COPD, Bronchiectasis, Sarcoidosis.

Overview

02036532006

Overview

Professor Onn Min Kon is a Consultant Respiratory Physician at OneWelbeck Lung Health.

About Professor Onn Min Kon

Alongside his work at OneWelbeck Professor Onn Min Kon is a Professor of Respiratory Medicine Imperial College London and a Consultant Respiratory Physician, Head of Service Tuberculosis Service.

Areas of Expertise

Professor Onn Min Kon treats various conditions including the following:

Some of the treatments and procedures offers are:

Lung function
CT scans
PET scans
Bronchoscopy
Endobronchial ultrasound needle aspirates

Additional Information

Memberships

President of the British Thoracic Society 2023
Meritorious Service Award, British Thoracic Society 2019
European Respiratory Society – Long Range Planning Committee Assembly 10
Past Chair of UK Joint Tuberculosis Committee
Chair of BTS MDR TB Clinical Advice Service from 2017-2024
NTM Network Management committee

Research Highlights

Key Publications

Drug-resistant tuberculosis treatments: the case for a phase III platform trial.
Yates TA, Barnes S, Dedicoat M, Kon OM, Kunst H, Lipman M, Millington KA, Nunn AJ, Phillips PP, Potter JL, Squire SB; UK Academics and Professionals to end TB.
Bull World Health Organ. 2024 Sep 1;102(9):657–664. doi: 10.2471/BLT.23.29094
TB PCR in BAL and EBUS-TBNA samples for the diagnosis of pulmonary and mediastinal lymph node TB: retrospective TRiBE study.
Park M, Kumar K, Coleman M, Martin L, Russell G, Scheelbeek P, Lalvani A, Satta G, Kon OM.
Thorax. 2024 Aug 19;79(9):870–877. doi: 10.1136/thorax-2023-220647.
Digital surveillance of ocular toxicity during TB treatment.
Dytko O, Park M, Nicholas R, Akshikar R, Kon OM.
Int J Tuberc Lung Dis. 2024 Jul 1;28(7):360–361. doi: 10.5588/ijtld.23.0500
Real-life use of delamanid: results from the European post-authorisation safety study.
Schönfeld N, Barkane L, Davoliene I, Danilovits M, Miliauskas S, Ader F, Kon OM, et al.
IJTLD Open. 2024 Jun 1;1(6):274–278. doi: 10.5588/ijtldopen.24.0113
Non-tuberculous mycobacterial pulmonary disease (NTM-PD): Epidemiology, diagnosis and multidisciplinary management.
Kumar K, Ponnuswamy A, Capstick TG, Chen C, McCabe D, et al., Kon OM, Lipman M, Loebinger MR, Dhasmana DJ.
Clin Med (Lond). 2024 Jan;24(1):100017. doi: 10.1016/j.clinme.2024.100017
Anti-tuberculosis drug-induced liver injury.
Lim WS, Avery A, Kon OM, Dedicoat M.
BMJ. 2023 Oct 27;383:e074866. doi: 10.1136/bmj-2023-07486
Transcriptomic signatures for diagnosing tuberculosis in clinical practice: a prospective, multicentre cohort study.
Hoang LT, Jain P, Pillay TD, Tolosa-Wright M, et al., Kon OM, Lalvani A.
Lancet Infect Dis. 2021 Mar;21(3):366–375. doi: 10.1016/S1473-3099(20)30928-2
Patterns of myocardial injury in recovered troponin-positive COVID-19 patients assessed by cardiovascular magnetic resonance.
Kotecha T, Knight DS, Razvi Y, Kumar K, et al., Kon OM.
Eur Heart J. 2021 May 14;42(19):1866–1878. doi: 10.1093/eurheartj/ehab075
Innate-like Gene Expression of Lung-Resident Memory CD8+ T Cells during Experimental Human Influenza: A Clinical Study.
Paterson S, Kar S, Ung SK, Gardener Z, et al., Kon OM, Openshaw PJ, Chiu C.
Am J Respir Crit Care Med. 2021 Oct 1;204(7):826–841. doi: 10.1164/rccm.202103-0620OC
Defining the Role of Cellular Immune Signatures in Diagnostic Evaluation of Suspected Tuberculosis.
Halliday A, Masonou T, Tolosa-Wright MR, Guo Y, et al., Kon OM, Lalvani A.
J Infect Dis. 2021 Jul 31:jiab311. doi: 10.1093/infdis/jiab311
Pulmonary Innate Lymphoid Cell Responses during Rhinovirus-induced Asthma Exacerbations In Vivo: A Clinical Trial.
Dhariwal J, Cameron A, Wong E, Paulsen M, et al., Kon OM, Johnston SL.
Am J Respir Crit Care Med. 2021 Dec 1;204(11):1259–1273. doi: 10.1164/rccm.202010-3754OC
Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study.
Evans RA, McAuley H, Harrison EM, Shikotra A, et al., Kon OM, Brightling CE; PHOSP-COVID Collaborative Group.
Lancet Respir Med. 2021 Nov;9(11):1275–1287. doi: 10.1016/S2213-2600(21)00383-0
Effect of CRTH2 antagonism on the response to experimental rhinovirus infection in asthma: a pilot randomised controlled trial.
Farne H, Glanville N, Johnson N, Kebadze T, et al., Kon OM, Jackson DJ.
Thorax. 2021 Oct 29. doi: 10.1136/thoraxjnl-2021-217429
Genomic signatures of pre-resistance in Mycobacterium tuberculosis.
Torres Ortiz A, Coronel J, Vidal JR, Bonilla C, et al., Kon OM, Grandjean L.
Nat Commun. 2021 Dec 15;12(1):7312. doi: 10.1038/s41467-021-27616-7
A cost comparison of amikacin therapy with bedaquiline, for drug-resistant tuberculosis in the UK.
Manalan K, Green N, Arnold A, Cooke GS, Dedicoat M, Lipman M, Loyse A, Harrison TS, Kon OM.
J Infect. 2020 Jan;80(1):38–41. doi: 10.1016/j.jinf.2019.09.006
Effectiveness of pre-entry active tuberculosis and post-entry latent tuberculosis screening in new entrants to the UK: a retrospective, population-based cohort study.
Berrocal-Almanza LC, Harris R, Lalor MK, Muzyamba MC, Were J, O'Connell AM, Mirza A, Kon OM, Lalvani A, Zenner D.
Lancet Infect Dis. 2019 Nov;19(11):1191–1201

Major insurers served

If your insurer is not listed, please contact us to confirm your coverage. Please note this does not guarantee coverage or fee assurance. Patients should confirm with their insurer to ensure coverage, check if the doctor is fee-assured, or verify if their policy includes the doctor in question.